2019
Quality Versus Quantity
Chiu AS, Arnold BN, Hoag JR, Herrin J, Kim CH, Salazar MC, Monsalve AF, Jean RA, Blasberg JD, Detterbeck FC, Gross CP, Boffa DJ. Quality Versus Quantity. Annals Of Surgery 2019, Publish Ahead of Print: &na;. PMID: 29697446, DOI: 10.1097/sla.0000000000002762.Peer-Reviewed Original ResearchConceptsComplex cancer surgeryCancer surgerySafe hospitalComplex oncologic surgeryPotential mortality reductionNational Cancer DatabaseHigh-volume hospitalsHospital quality measuresSurgical mortalityPrimary cancerHospital rating systemsOncologic surgeryCancer DatabaseMortality reductionSurgical volumeHospital safetyPatient realignmentPatientsHospitalSurgeryMeaningful reductionPublic reportingMortalityRSMRCancer
2013
Stage Classification and Prediction of Prognosis: Difference between Accountants and Speculators
Detterbeck F. Stage Classification and Prediction of Prognosis: Difference between Accountants and Speculators. Journal Of Thoracic Oncology 2013, 8: 820-822. PMID: 23774383, DOI: 10.1097/jto.0b013e318293d98c.Peer-Reviewed Original Research
2003
A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors
Poole ME, Bernard SA, Churchel MA, Weissler MC, Calvo B, Cance W, Ollila D, Koruda M, Behrns K, Detterbeck FC. A Phase I Study of Gemcitabine and Docetaxel for Advanced Stage Solid Tumors. Cancer Investigation 2003, 21: 350-354. PMID: 12901280, DOI: 10.1081/cnv-120018225.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityDose of docetaxelPhase IDay 1Solid tumorsAdvanced-stage solid tumorsSignificant nonhematologic toxicityPhase II studyRefractory solid tumorsPhase I studiesM2 i.Nonhematologic toxicityStable diseaseStarting doseII studyPartial responseHypersensitivity reactionsI studiesGastric cancerPrimary siteGemcitabinePatientsDocetaxelDoseConstant dose